Influenza virus infection
Conditions
Interventions
peramivir. 600-mg of peramivir once a day, are administered intravenously over a period of 15 to 60 min for 1 to 5 days as needed.
Oseltamivir. 75mg of oral oseltamivir twice a day for 5 consecuti
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) >=20 years old (ii) Influenza rapid antigen test; positive (iii) At least one risk factor: poorly controlled diabetes (hemoglobin A1c >=7.0%), chronic respiratory tract disease, chronic heart disease, chronic liver disease, chronic renal disease, malignancy, collagen vascular disease and current use of a drug that suppresses immune function (immunosuppressant drug or adrenocortical hormone preparation equivalent to >=10 mg/day of prednisolone) (iv) Onset of influenza symptoms within the previous 48h (v) At least two of the seven influenza symptoms: headache, muscle or joint pain, fever or chills, fatigue, cough, sore throat, and nasal congestion
Exclusion criteria
Exclusion criteria: (i) Chronic respiratory failure requiring artificial ventilation (ii) Diabetes with an HbA1c value of >=10% (iii) Organ transplant or hematopoietic stem cell transplant within the previous 12 months (iv) Requirement for dialysis or presence of nephropathy (estimated creatinine clearance, <50 ml/min) (v) Presence of a complicating infection judged to require treatment by systemic administration of an antimicrobial agent (vi) Contraindication of peramivir and oseltamivir (vii) Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of influenza illness | — |
Secondary
| Measure | Time frame |
|---|---|
| The duration of fever, Complications | — |
Countries
Japan
Contacts
Public ContactTaisuke Akamatsu
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed